Related Experiment Video
Updated: May 13, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets.
Francesco Rocco Bertuccio1,2, Simone Montini1,2, Maria Antonietta Fusco1,2
1Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy.
Pleural mesothelioma (PM) is a rare cancer with poor prognosis. Research into its genetic landscape and novel therapeutic targets offers hope for improved treatment strategies and patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Pleural mesothelioma (PM) is an aggressive cancer linked to asbestos, genetics, and mutations.
- Current treatments offer limited survival benefits, with a median of 6-18 months.
Purpose of the Study:
- To review advancements in understanding PM's molecular and genetic basis.
- To identify promising therapeutic targets and evaluate emerging clinical trial data.
Main Methods:
- Comprehensive review of genetic and epigenetic alterations in PM.
- Analysis of key signaling pathways implicated in PM development.
- Examination of novel therapeutic targets and ongoing clinical trials.
Main Results:
- Identification of numerous potential therapeutic targets.
- Emerging clinical trials show promising efficacy for novel strategies.
- Understanding of PM's genetic and epigenetic landscape is advancing.
Conclusions:
- Novel therapeutic strategies targeting PM's molecular landscape are under investigation.
- Precision medicine approaches hold potential for improving patient prognosis.
- Continued research and clinical trials are crucial for advancing PM treatment.
More Related Videos
Related Concept Videos
Pleural Disorders: Types and Brief Description
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

